Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Xpeng Inc - ADR — how do they compare? Vertex Pharmaceuticals Incorporated trades at $528.72 (market cap $134.25B), while Xpeng Inc - ADR trades at $11.77 (market cap $11.15B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 12× Xpeng Inc - ADR's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Xpeng Inc - ADR nearer its low. Which is the better fit depends on your goals.
| VRTX | XPEV | |
|---|---|---|
Market Cap | $134.25B | $11.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $529.65 | $28.07 |
52-Week Low | $376.62 | $11.68 |
Enterprise Value | $128.37B | $13.28B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $523.91, up 5.61% with strong technical momentum and bullish moving averages. The company reported Q2 2026 revenue growth of 12% to $3.3 billion, beating expectations despite an EPS miss, and raised its full-year 2026 revenue guidance. Valuation metrics show a P/E of 30.85 and P/S of 10.78, while maintaining robust profitability with 86% gross margins and 35% net income margins.
Outlook remains positive with analyst consensus strongly bullish (84% buy ratings) and a $534.25 price target. Key risks include execution on newer product launches and competitive pressures in cystic fibrosis treatments. The stock's current momentum suggests continued upside potential, though RSI levels indicate potential near-term overbought conditions.
XPeng (XPEV) trades at $12.00, down 1.07% on the day, with a bearish technical signal. The company reported Q1 2026 revenue of $76.72 billion but a net loss of $1.14 billion, though the net margin improved to -1.49% from -14.17% in 2024. Recent news highlights vehicle delivery growth, international expansion, and advancements in autonomous driving technology.
The outlook is mixed: strong revenue growth and analyst buy ratings (64.7% consensus) suggest upside to the $17.00 price target, but persistent losses, high EV/EBITDA of 40.09, and competitive pressures pose risks. Investor sentiment is cautious amid earnings volatility and macroeconomic headwinds in the EV sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
